New drug combo for HER2-positive breast cancer before surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests a new targeted drug (BL-M07D1) with or without another drug called pertuzumab, compared to a standard chemotherapy plus two targeted drugs, before surgery for HER2-positive breast cancer. The goal is to see if the new combination works better at shrinking tumors before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive breast cancer that can be removed with surgery.
- Your cancer is stage II or III (not spread to distant organs).
- You are a woman aged 18 to 75.
- You have not had any prior treatment for this breast cancer.
- You are healthy enough for daily activities (ECOG 0 or 1) and have adequate organ function.
- If you could become pregnant, you must use effective birth control during and for 7 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new cancer drug called BL-M07D1, combined with pertuzumab, works better or as well as standard chemotherapy for advanced HER2-positive breast cancer that has spread or come back. HER2-positive means the cancer cells have high levels of a protein called HER2, which makes them grow faster.
This trial tests a new drug called trastuzumab rezetecan given before surgery for early-stage HER2-positive breast cancer. It's designed for patients whose cancer doesn't respond well to standard HER2-targeted treatments.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.